Physician profile
George Dy
NPI 1962415067
$42,372.82
in general payments reported to CMS, 2019-2025
48 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $1,984 · 2021: $6,131 · 2022: $7,942 · 2023: $3,167 · 2024: $1,751 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,745 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,550 · Consulting Fee: $120 · Education: $21.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,745.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,550.00 |
| Consulting Fee | $120.00 |
| Education | $21.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19,985.70 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $12,654.28 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,653.46 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $977.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $867.09 | 2019-2025 | Trelegy Ellipta, Shingrix, Jemperli |
| Lilly USA, LLC | $859.00 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.54 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $476.83 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $437.41 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $395.96 | 2019-2024 | |
| Dexcom, INC. | $355.35 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $288.07 | 2019-2025 | |
| Abbvie INC. | $285.16 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $248.38 | 2019-2024 | Eliquis, Camzyos |
| Abbott Laboratories | $224.85 | 2021-2025 | Freestyle Libre 3 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $211.02 | 2019-2025 | Veozah, Myrbetriq |
| Mallinckrodt Enterprises LLC | $196.29 | 2019 | |
| Ardelyx, INC. | $180.31 | 2023-2025 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $176.37 | 2019-2022 | |
| Amarin Pharma, INC. | $135.52 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $106.72 | 2024 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $93.17 | 2019-2022 | |
| Genzyme Corporation | $85.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.72 | 2019-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $83.37 | 2023-2025 | Jynarque, Rexulti |
| Xeris Pharmaceuticals, INC. | $73.83 | 2021-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $73.46 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $71.89 | 2020-2021 | |
| Exact Sciences Corporation | $60.26 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Aurinia Pharma U.S., INC. | $57.43 | 2023 | Lupkynis |
| Radius Health, INC. | $56.69 | 2020-2021 | |
| Horizon Therapeutics Plc | $53.00 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $47.05 | 2022 | |
| Verona Pharma, INC. | $42.27 | 2025 | Ohtuvayre |
| Alexion Pharmaceuticals, INC. | $36.06 | 2022-2024 | Ultomiris |
| Akebia Therapeutics INC | $31.20 | 2019 | |
| Philips North America LLC | $25.78 | 2021 | |
| Allergan, INC. | $24.38 | 2019-2020 | |
| Lundbeck LLC | $21.26 | 2024 | Rexulti |
| Travere Therapeutics, INC. | $20.26 | 2025 | |
| Cmp Pharma, INC. | $20.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.99 | 2022 | |
| Pulmonx Corporation | $19.14 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Calliditas Therapeutics US INC. | $16.16 | 2022 | |
| Scpharmaceuticals INC. | $13.83 | 2024 | |
| Grifols USA, LLC | $13.06 | 2022 | |
| Medicure Pharma INC. | $11.71 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Dy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.